. . . "A MHC fusion complex that contains a presenting peptide that is a T-cell receptor antagonist or partial agonist is particularly preferred for treatment of allergies and autoimmune diseases such as multiple sclerosis, insulin-dependent diabetes mellitus and rheumatoid arthritis. [0216] Further, as discussed above and in said PCT application No. WO 96/04314, host compatible antigen presenting cells" .